Volume 25, Issue 7 586702 pp. 373-376
Open Access

Should Albumin Be Used in All Patients with Spontaneous Bacterial Peritonitis?

Neeraj Narula

Neeraj Narula

Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute; McMaster University Hamilton Ontario, Canada

Search for more papers by this author
Keith Tsoi

Keith Tsoi

Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute; McMaster University Hamilton Ontario, Canada

Search for more papers by this author
John K Marshall

Corresponding Author

John K Marshall

Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute; McMaster University Hamilton Ontario, Canada

Search for more papers by this author
First published: 2011
Citations: 12

Abstract

Patients with cirrhosis who develop spontaneous bacterial peritonitis (SBP) have been reported to experience a high incidence of renal impairment and mortality. Renal dysfunction is possibly related to altered systemic hemodynamics that leads to decreased effective arterial blood volume. Albumin, a plasma volume expander, has been investigated to determine whether it plays a role in patients with SBP. The current literature suggests that albumin can reduce renal impairment and mortality in high-risk SBP patients, defined as patients with a serum bilirubin level of greater than 68.4 μmol/L, a blood urea nitrogen level of greater than 10.7 mmol/L or a serum creatinine level greater than 88.4 μmol/L. The rationale for albumin and other volume expanders in SBP is discussed, accompanied by a review of the current literature.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.